Hints and tips:
...It remains our top pick, alongside LUPE which we continue to prefer over AKERBP, given greater capital flexibility, though LUPE does need to address its 2C shortfall in the near term....
...(It even has Lupe Fiasco!) — Your latest ‘pharma is really bad’ story: “Drug maker thwarted plan to limit OxyContin prescriptions at dawn of opioid epidemic”....
International Edition